The transaction includes an upfront fee of $150 million and will give BMS a worldwide licence for PRM-151, a recombinant form of human pentraxin-2 protein which is in development for the treatment ...

The recombinant human pentraxin-2 (PTX-2) drug is no longer listed in Roche’s R&D pipeline, and was previously in development for idiopathic pulmonary fibrosis (IPF), as well as Crohn’s disease.

We investigated the involvement of cellular crosstalk in regulating cell state dynamics and identified pentraxin-3 and hepatocyte growth factor as potential modulators of PASMC phenotypic transition ...

Neuronal pentraxin was not significant. The negative predictive values for increasing synaptopodin and decreasing NGAL was 70.0% and 90.9%, respectively. Conclusions and relevance Our results indicate ...

Serum autotaxin levels are significantly elevated in patients with migraine and correlate with headache severity, ...

I joined the University of Sheffield in 2002 as a Senior Clinical Lecturer in Cardiology and subsequently became Professor of Cardiology in January 2011. I am Clinical Lead for the Cardiovascular ...

In this research group, the research areas of global surgery and reconstructive plastic surgery meet. The research is to a large extent focused on the development and improvement of surgical health ...

Department of Clinical Pharmacy and Pharmacy Administration, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, ...

Shift work is associated with systemic chronic inflammation, impaired host and tumor defense and dysregulated immune responses to harmless antigens such as allergens or auto-antigens. Thus, shift ...